Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius AGSARTF 82 3-Year Share Buyback Ratio is -0.30 as of Mar. 2026. GuruFocus rates SARTF with a GF Score™ of 82/100 and a GF Value™ of $274.15 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 615 Medical Devices & Instruments companies, Sartorius AG ranks better than 73.17% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Sartorius AG's current 3-Year Share Buyback Ratio was -0.30%.
The historical rank and industry rank for Sartorius AG's 3-Year Share Buyback Ratio or its related term are showing as below:
SARTF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3 Med: 0 Max: 0
Current: -0.3
During the past 13 years, Sartorius AG's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -0.30%. And the median was 0.00%.
SARTF's 3-Year Share Buyback Ratio is ranked better than 73.17% of 615
companies
in the Medical Devices & Instruments industry
Industry Median: -2.7
vs SARTF: -0.30
Sartorius AG (OTCPK:SARTF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Sartorius AG 3-Year Share Buyback Ratio Related Terms
SARTF vs ISRG, BDX, MDLN: 3-Year Share Buyback Ratio Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Sartorius AG's 3-Year Share Buyback Ratio falls into.
Sartorius AG 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -0.30 mean?
Sartorius AG (SARTF) has a 3-Year Share Buyback Ratio of -0.30 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Sartorius AG and its competitors. According to the industry distribution chart, Sartorius AG ranks #165 out of 615 companies in the Medical Devices & Instruments industry, placing it in the top 26.8%.
Is Sartorius AG's 3-Year Share Buyback Ratio too high?
Sartorius AG's current 3-Year Share Buyback Ratio is -0.30. Based on the distribution chart, Sartorius AG ranks #165 out of 615 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius AG has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's 3-Year Share Buyback Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #165 out of 615 companies for 3-Year Share Buyback Ratio. This puts Sartorius AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Sartorius AG and its competitors. Sartorius AG's current 3-Year Share Buyback Ratio is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $274.15, compared to a current price of $212.80 — trading 22.4% below its estimated fair value. The current 3-Year Share Buyback Ratio is -0.30. Sartorius AG's overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Sartorius AG (SARTF), the current 3-Year Share Buyback Ratio is -0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 22.4% below its estimated GF Value™ of $274.15.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
3-Year Share Buyback Ratio: -0.30
GF Value™: $274.15 vs. price of $212.80 (22.4% below fair value)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
82GF Score
Get the complete analysis for SARTF
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
